JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267070

Human PARP14 knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PARP14 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 4 and 2 bp insertion in exon 4. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human PARP14 knockout A549 cell line (AB267070)
  • Sanger seq

Unknown

Sanger Sequencing - Human PARP14 knockout A549 cell line (AB267070)

Allele-2 : 2 bp insertion in exon 4.

Sanger Sequencing - Human PARP14 knockout A549 cell line (AB267070)
  • Sanger seq

Unknown

Sanger Sequencing - Human PARP14 knockout A549 cell line (AB267070)

Allele-1 : 1 bp insertion in exon4

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 4 and 2 bp insertion in exon 4

Disease

Carcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267070-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267070 Human PARP14 knockout A549 cell line", "number":"AB267070-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267070-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267070-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267070-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab267070 Human PARP14 knockout A549 cell line", "number":"AB267070-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267070-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267070 Human PARP14 knockout A549 cell line", "number":"AB267070-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267070-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267070 Human PARP14 knockout A549 cell line", "number":"AB267070-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PARP14
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PARP14 also known as ADP-ribosyltransferase diphtheria toxin-like 8 (ARTD8) is a member of the poly(ADP-ribose) polymerase (PARP) family. It has a molecular mass approximately 180 kDa and is mainly found in the nucleus though it also localizes to the cytoplasm. This enzyme involves mono-ADP-ribosylation a process attaching ADP-ribose to target proteins which affects protein function and stability. It is expressed in various tissues with significant presence in immune cells.
Biological function summary

PARP14 participates in cell signaling and immune response regulation. It does not directly form part of a specific protein complex but interacts with several proteins influencing transcription and immune cell differentiation. PARP14 modulates the function of STAT6 a transcription factor vital for IL-4 induced gene expression in Th2 cell differentiation. This modulation plays a significant role in maintaining immune homeostasis and facilitating cellular communication during an immune response.

Pathways

PARP14 plays an integral role in the JAK-STAT and NF-kB signaling pathways. In the JAK-STAT pathway PARP14 modifies STAT6 activity which affects cytokine signaling and immune responses. Through the NF-kB pathway PARP14 can influence cell survival and inflammation by acting in combination with other PARP family members like PARP1 which shares a role in ADP-ribosylation signaling. These interactions ensure proper regulation of cellular stress responses and transcriptional activities.

PARP14 associations connect to cancer and inflammatory diseases. Its dysregulation can lead to altered immune responses which relate to cancers such as lymphoma. Additionally PARP14 influences inflammatory processes linked to disorders like asthma. Within these diseases abnormal PARP14 activity sometimes involves cross-talk with proteins like STAT6 in cancer pointing to its role in tumor-promoting inflammation and cell proliferation.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com